Real-World Evidence of Immunotherapy Sequencing in Multiple Myeloma: Durable Responses With BCMA-Targeting Bispecific Antibodies Following Prior GPRC5D-Targeting Therapy
Multiple immunotherapy drugs can be used one after another in myeloma, giving patients sequential treatment options when one approach stops working.
A retrospective real-world study evaluated BCMA-targeting bispecific antibody therapy following GPRC5D-targeting bispecific therapy in multiple myeloma, documenting durable response rates in this emerging sequential immunotherapy approach. This addresses a critical clinical question about bispecific antibody sequencing in an era where multiple immunotherapy targets are available for R/R myeloma patients.
What the study was
- Study design
- Retrospective real-world observational study of bispecific antibody sequencing in R/R multiple myeloma
- Population
- Multiple myeloma patients previously treated with GPRC5D-targeting bispecific therapy
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Clin Lymphoma Myeloma Leuk
Why it surfaced
Real-world bispecific antibody sequencing data in myeloma (GPRC5D then BCMA); addresses emerging clinical question; classification_confidence=low — abstract not fully retrieved, largely title-inferred.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.